## Note
nid: 1497068228215
model: AnKingOverhaul
tags: #AK_Original_Decks::Step_1::Zanki_Pharmacology, #AK_Step1_v11::#FirstAid::02_Immunology::04_Immunosuppressants::04_Therapeutic_Antibodies::Pembrolizumab, #AK_Step1_v11::#FirstAid::04_Pathology::03_Neoplasia::05_Immune_Checkpoint_Interactions, #AK_Step1_v11::#FirstAid::04_Pathology::03_Neoplasia::05_Immune_Checkpoint_Interactions::Pembrolizumab, #AK_Step1_v11::#OME_banner, #AK_Step1_v11::#SketchyPharm::08_Antineoplastics::Cancer_Immunotherapy, #AK_Step1_v11::^Other::^EXPN, #AK_Step1_v11::^Other::^HighYield::1-HighYield
markdown: false

### Text
<div>
  <div style="font-weight: bold;">
    <b>Pembrolizumab</b> is indicated for the treatment of
    {{c1::<b>all solid tumors</b>}} that bear a(n)
    {{c2::<b>PD-L1</b>}} mutation
  </div>
</div>

### Extra
<i>Pembrolizumab binds to the PD1 receptor on T cells, preventing
aberrant PD-L1 expression from stimulating it</i>
<div>
  <i><img src="immune-checkpoint-enlarge.__v100154616.jpg" style=
  "width: 693px;"></i>
</div>

### Lecture Notes


### Missed Questions


### Pathoma


### Boards and Beyond


### First Aid


### Sketchy
#REF!

### Pixorize


### Physeo


### OME
<div class="ome-widget">
  <a href="https://onlinemeded.org?ref=anki"><img src=
  "_OME_AnkiFlashcards_General_3.png"></a>
</div>

### Additional Resources


### One by one

